XOSPATA Is the First FDA-Approved Inhibitor for Relapsed or Refractory FLT3m+ AML to Target ITD and TKD Mutations1

  • XOSPATA is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT31
  • XOSPATA demonstrated the ability to inhibit FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 mutations, including1:
    • FLT3-ITD
    • FLT3-TKD (FLT3-D835Y)
    • FLT3-ITD and FLT3-TKD (FLT3-ITD-D835Y)
  • Additionally, XOSPATA induced apoptosis in leukemic cells expressing FLT3-ITD1

Mechanism of Action for XOSPATA2,3

Mechanism of Action for XOSPATA Mechanism of Action for XOSPATA
The clinical significance of the preclinical studies is unknown.
Select Safety Information

Prolonged QT Interval XOSPATA has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with XOSPATA, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration.

AML=acute myeloid leukemia; FDA=Food and Drug Administration; FLT3=FMS-like tyrosine kinase 3; ITD=internal tandem duplication; m+=mutation positive; TKD=tyrosine kinase domain.